Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 6, 2005. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general corporate financial performance.
Material Changes
The filing details a re-valuation of the cash element of a notional investment held within the US Retirement Savings Plan. This resulted in an increase in the notional allocation of Ordinary Share ADRs for Dr. R Greig on December 2, 2005, at a price of $51.04 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure Rule 3.1.4R(1)(a).
Key Facts for Investors to Verify
- The transaction involves a notional increase in ADR allocation for Dr. R Greig within the US Retirement Savings Plan.
- The transaction price was $51.04 per share on December 2, 2005.
- This filing does not contain consolidated financial results for the company.